Louisiana officials asked the U.S. Supreme Court on Thursday to maintain a lower-court order blocking the mailing of the abortion drug mifepristone [1].
The outcome of this request could determine whether patients nationwide can access the medication through mail-order services or if state-level restrictions can effectively halt the drug's distribution across borders.
The filing was submitted Thursday afternoon, May 7, 2026, to the court in Washington, D.C. [1, 3]. The request seeks to preserve a ruling from the U.S. Court of Appeals for the 5th Circuit in New Orleans, which barred the mailing of the medication [1, 3].
State officials said the block is necessary to align with Louisiana's own abortion restrictions [1, 3]. By preventing the mailing of mifepristone, the state aims to stop nationwide access to the pill, a primary method for terminating early pregnancies in areas where clinics are unavailable.
This legal move follows efforts by medication providers to overturn the restriction. Two makers of mifepristone filed emergency appeals to the Supreme Court to challenge the order [4].
The 5th Circuit's order remains a central point of contention in the broader legal battle over medication abortion. Louisiana said it wants the high court to leave the status quo in place while the legal merits of the case are debated [1, 2].
“Louisiana urged the U.S. Supreme Court to keep in place a lower‑court order that blocks the mailing of the abortion medication mifepristone.”
This legal maneuver represents an attempt by state governments to extend their regulatory reach beyond their own borders. If the Supreme Court upholds the block, it would establish a precedent that state-level restrictions on medication can override the federal postal system's ability to deliver FDA-approved drugs, potentially creating a fragmented landscape of healthcare access across the U.S.
